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Radio frequency ablation (RFA) of lung tumors is a rela-tively new procedure allowing local treatment with min-
imal parenchymal damage. This technique is able to induce
coagulative necrosis in a limited pulmonary area.1 This emerg-
ing technology is used to achieve local treatment of primary and
secondary lung tumors in patients with poor clinical status or
technical contraindications to surgical resection.2,3
MATERIALS AND METHODS
Preoperative patient assessment is the same methodol-
ogy used for major pulmonary resection. The current election
criteria include contraindication to surgical treatment; maxi-
mal diameter of the tumor less than or equal to 5 cm; lesions
located more than 1 cm from major blood vessels or airways;
patients with platelet count of more than 50  103/L.
To produce monopolar radiofrequency energy, we used
an automatic apparatus with maximal power output of 150 W
operating at 460 Hz (Model 1500; RITA Medical System,
Mountain View, CA). It has multiple temperature displays
and impedance and power monitoring, and software is avail-
able to record and graphically represent all the data on a
personal computer. The energy is transferred to the tissue by
means of a multi-tined expandable array (Starburst XL; RITA
Medical System). It consists of a 15-gauge needle cannula
with nine deployable electrodes that open flower-like up to 5
cm. Five electrodes are equipped with thermocouples that
allow continuous measurement of the temperature inside the
tissue. Two grounding pads are applied to each shaved leg to
ground the current and to reduce risks of skin thermal injury.
The procedure is performed with the patients under
conscious sedation (ketorolac 0.5–0.8 mg/kg, propofol 1–2
mg/kg/h, and remifentanil 0.1mg/kg/min) and local anesthe-
sia (subcutaneous 1% xylocaine). Vital signs are continu-
ously, non-invasively monitored. Computed tomographic
(CT) guidance is used in most cases; it is usually enhanced by
the administration of contrast material before and after coag-
ulation to obtain information about the real effectiveness of
the procedure. In a selected group of patients with the tumor
in contact with the thoracic wall, it is possible to work under
ultrasound guidance. The needle electrode is inserted through
an intercostal space after administration of local anesthesia.
The correct placement is confirmed by CT or ultrasound
before applying the radiofrequency energy. The target tem-
perature of ablation is 90°C. It is maintained for 15 to 27
minutes according to the size of the tumor; this variable also
determines the gradual deployment of the electrodes, starting
from 2 cm and then 1 cm for each step. When technically
feasible, the ablation zone should include the whole lesion
and 1 cm of the surrounding lung parenchyma.
After RFA, the ablation zone is generally visible at CT
scan as a ground glass opacity surrounding the target lesion.
After the procedure, the patient is transferred to the recovery
room for observation. Twenty-four hours later, after perform-
ing a chest radiograph to exclude the occurrence of any
complication (e.g., pneumothorax), the patient is discharged.
Radiological follow-up includes contrast-enhanced CT
at 1, 3, and 6 months and then at 6-month intervals.
RESULTS
Since 2001, we have performed more than 100 RFA of
lung tumors. In 50 cases, radiofrequency ablation was used
for non-small cell lung cancer (NSCLC) for 42 men and 8
women with mean age of 73.7 years (range, 51–89 years).
RFA was performed because of medical contraindica-
tion to surgery in 36 patients with stage I NSCLC and because
of advanced disease in 14 cases, often with an integrated ther-
apeutic approach.
All the procedures were well tolerated. We observed no
mortality, and morbidity consisted of five cases of partial pneu-
mothorax (10%), two of which required pleural drainage.
At a median follow-up period of 31 months, the overall
radiological complete response rate was 59%, and median
survival was 25 months (61% and 28.9 months, respectively,
in stage I disease).
DISCUSSION
After the first percutaneous RFA of lung lesions reported
by Dupuy et al. in 2000,4 a number of works have described the
feasibility and safety of the procedure. In particular, an
international survey with almost 500 RFA of lung tumors
reported by Steinke and colleagues in 2004 stressed the low
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invasiveness approach of this technique, negligible mortality,
low morbidity, short hospital stay, and quality of life im-
provement.5
Most of the reports address short-term results with
encouraging data. Herrera et al.3 treated a mixed cohort of 18
patients (5 via thoracotomy and 13 percutaneously) with
primary and metastatic lung tumors. They used a needle
electrode with multiple tines deployable into the tumor for 2
or 4 cm. After a mean follow-up of 6 months, they reported
a 55% complete or partial response rate and a 17% stable
disease rate in lesions with a mean diameter of 5.3 cm. The
response rates seemed to be better for smaller lesions (66%
for lesions smaller than 5 cm vs 33% for lesions larger than
5 cm). Another important issue that arose in that study was
the contraindication to treat central lesions because of the risk
of fatal complications, as occurred in one case in that series.
More recently, Fernando and colleagues from the same Insti-
tute presented an update of their experience in patients with
primary NSCLC.6 At a mean follow-up period of 14 months,
they reported 63% of the patients having a complete re-
sponse, which is comparable to our results. In a series of 54
primary and secondary lung tumors, Akebosi et al. reported a
complete necrosis rate of 59%, with a better response for
smaller lesions.7 They distinguished lesions smaller than or
equal to 3 cm from lesions greater than 3 cm and found a
statistically significant difference in the complete response
rate between the two groups (69% vs 39%; p  0.05). These
findings were confirmed by Lee and colleagues,8 who re-
ported a complete necrosis rate of 38% at a mean follow-up
of 12.5 months with a statistically significant difference for
lesions smaller than 3 cm (100% complete necrosis rate)
compared with those measuring 3 to 5 cm (38%; p  0.05)
and those larger than 5 cm (only 8% complete necrosis rate).
We have recently reported our experience with medium-term
results.9 Our data confirm all the previous reports, with an
overall radiological complete response rate (CRR) of 61.9%
(39 of 63 lesions) at a mean follow-up period of 23.7 months
(median 24; range, 6–50). The results seemed to be better for
lesions smaller than 3 cm (CRR 69.7% vs 50%). Moreover, in
our study, pulmonary function tests performed before and
after RFA at several time points showed a slight reduction of
FVC and FEV1 at the end of the first month (not statistically
significant), but they returned to pretreatment values after 3
months.
RFA of lung tumors may also be combined with other
treatment options (e.g., radiotherapy and chemotherapy) to
have more control of the disease. In fact, Grieco et al. obtained
better results with RFA combined with RT compared with either
modality alone. At a median follow-up period of 19.5 months,
they reported a CRR of 75.6%.10 Instead, in an experimental
study on an animal model, Ahmed and colleagues achieved
an increase in tumor destruction combining RFA with intra-
venous administration of liposomal doxorubicin.11
In conclusion, RFA of lung tumors may play a role in
the treatment of NSCLC. Expected further improvements of
the technology and combinations with other therapies may
increase its efficacy. However, it is important to stress that
RFA is devoted to local treatment of lesions, and this is
certainly a limitation of this procedure. Compared with sur-
gical resection, it has a higher incidence of local and distant
recurrence. For this reason, this procedure should only be
intended as a compromise in treating patients who are at high
risk for surgical resection because of their clinical status.
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